 | HIV
and Hepatitis.com
Coverage of
the 13th Annual Conference on Retroviruses and Opportunistic Infections February 5 - 8, 2006, Denver, CO |
In
HCV Genotype
1 Patients with
Low Viral Load,
Pegasys Plus
Ribavirin Produces
an SVR Rate
Similar to That
in Genotype
2/3 pts with
Low or High
Viral Load In HCV
monoinfection,
genotype
1 patients
experience high
sustained
virologic response
rates (SVR)
providing they
achieve a rapid
virologic response
(RVR)
at 4 weeks following
initiation of
therapy, regardless
of their baseline
HCV viral load.
In the
current study,
Douglas Dieterich
and others evaluated
the effect of
an RVR on the
probability
of an SVR in
genotype 1 patients
who received
PEG
IFNa-2a
(Pegasys) +
ribavirin (RBV) in the
AIDS
Pegasys Ribavirin
International
Co-infection
Trial (APRICOT). Click
on study title
to view abstract
on 13th
CROI website:
Sustained
Virologic Response
(SVR) in HIV-HCV
Co-infected
Patients with
HCV Genotype
1(G1) Infection
who have a Rapid
Virological
Response (RVR)
at Week 4 of
Treatment with
Peginterferon
Alfa-2a (40KD)
(PEG IFNalpha-2a,
PEGASYSŪ) Plus
Ribavirin (RBV,
COPEGUSŪ): AIDS
PEGASYS Ribavirin
International
Co-infection
Trial (APRICOT).
13th Conference
on Retroviruses
and Opportunistic
Infections,
February 5-8,
2006. Denver,
Co. Abstract
856.
| ||
